Regeneron Pushes Legal, Ethical Boundaries With Offer Of COVID-19 Antibody To Biden Campaign

Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.

Regeneron Pharmaceuticals, Inc.’s move to publicly broadcast its decision to “offer” Democratic Presidential Candidate Joe Biden’s team access to its experimental cocktail of two monoclonal antibodies for COVID-19 may run afoul of US Food and Drug Administration regulations surrounding promotion of unapproved products.

Any chance of the agency taking enforcement action seems remote, but the incident underscores the legal and ethical minefields that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Marketing & Advertising

More from Compliance